Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2025-02-12 00:00:00 ET · period of report 2025-02-10 · accession 0000875320-25-000039 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-02-12 | 2025-02-10 | VRTX | Biller Jonathan | EVP, CLO | F - Tax | $467.98 | -1,632 | 19.8K | -8% | -$763.7K | |
| 2025-02-12 | 2025-02-11 | VRTX | Biller Jonathan | EVP, CLO | S - Sale | $459.87 | -3,433 | 16.3K | -17% | -$1.58M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-10 | F | D | 1,632 | $467.98 | 19,763 | D | — | — | |
| 2 | Common | Common Stock | 2025-02-11 | S | D | 3,433 | $459.87 | 16,330 | D | — | — | (F3) Open market sales reported on this line occurred at a weighted average price of $459.87 (range $459.83 to $460.00). (F2) Mr. Biller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |